Exicure, Inc. (XCUR)
$1.15+5.50%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $7M
- Beta
- 3.63
- P/E (TTM)
- -0.88
- Short % float
- 2.10%
- Days to cover
- 2.0
- SI change
- -46.9%
- 1W
- +6.48%
- 1M
- -16.06%
- vs SPY 1W
- +6.62%
- vs SPY 1M
- -18.56%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 2
- VALUE
- 0
- GROWTH
- 35
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-142.7%
REV YoY-
ROE-237.9%
EPS YoY-
ROA-72.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.88
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B7.50
P/FCF-
EV/EBITDA-0.66
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.56
ND/EBITDA-
BETA3.63
Company news
FAQ
- What is LOPJLB’s current signal on XCUR?
- LOPJLB’s latest quantitative signal on Exicure, Inc. (XCUR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is XCUR in?
- Exicure, Inc. (XCUR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Exicure, Inc. (XCUR) do?
- Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood …